Cardiac troponins T and I are critical biomarkers for the diagnosis of myocardial infarction, but require clinical context due to potential elevation in non-ischemic conditions.
Answers are grounded in this paper and cite their sources.
Requires clinical context to avoid misinterpreting non-MI troponin rises; leaves open threshold optimization in comorbidities.
The cardiac troponins T (cTnT) and I (cTnI) can be measured by immunoassay systems and provide key biochemical information in patients with an acute coronary syndrome. Cardiac troponins are released only after cardiac damage has occurred and are sensitive and specific for myonecrosis. In this article, the clinical role of troponin measurement is illustrated in the diagnosis and management of three categories of patients: those in whom ST segment elevation is shown on the ECG; those with possible acute coronary syndrome at high risk of non-ST elevation acute myocardial infarction; and those with low risk/possible acute coronary syndrome. However, both cTnT and cTnI values can be raised in disorders resulting from causes other than myocardial infarction, for example, in renal failure and after percutaneous coronary intervention. These situations are discussed.
No takes yet. Share an insight, caveat, or question.
Paul Collinson (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: